Literature DB >> 26907883

Pancreatic cancer: CYP3A5 contributes to PDAC chemoresistance.

Hugh Thomas.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26907883     DOI: 10.1038/nrgastro.2016.36

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.

Authors:  Elisa M Noll; Christian Eisen; Albrecht Stenzinger; Elisa Espinet; Alexander Muckenhuber; Corinna Klein; Vanessa Vogel; Bernd Klaus; Wiebke Nadler; Christoph Rösli; Christian Lutz; Michael Kulke; Jan Engelhardt; Franziska M Zickgraf; Octavio Espinosa; Matthias Schlesner; Xiaoqi Jiang; Annette Kopp-Schneider; Peter Neuhaus; Marcus Bahra; Bruno V Sinn; Roland Eils; Nathalia A Giese; Thilo Hackert; Oliver Strobel; Jens Werner; Markus W Büchler; Wilko Weichert; Andreas Trumpp; Martin R Sprick
Journal:  Nat Med       Date:  2016-02-08       Impact factor: 53.440

  1 in total
  1 in total

1.  Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer.

Authors:  Chundong Cheng; Danxi Liu; Zonglin Liu; Mengyang Li; Yongwei Wang; Bei Sun; Rui Kong; Hua Chen; Gang Wang; Le Li; Jisheng Hu; Yilong Li; Hongze Chen; Zhongjie Zhao; Tao Zhang; Siqiang Zhu; Shangha Pan
Journal:  Cancer Sci       Date:  2022-05-23       Impact factor: 6.518

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.